
Topical Application of Heterologous Protein-Expressing Staphylococcus Epidermidis for Potential Therapeutic Treatment of Skin DiseasesAward last edited on: 1/9/19
Sponsored Program
STTRAwarding Agency
NIH : NIAIDTotal Award Amount
$150,000Award Phase
1Solicitation Topic Code
-----Principal Investigator
Travis M WhitfillCompany Information
Phase I
Contract Number: 1R41AI130373-01Start Date: 8/15/16 Completed: 7/31/17
Phase I year
2016Phase I Amount
$150,000Public Health Relevance Statement:
PROJECT NARRATIVE The proposal aims to establish proof-of-concept that a platform can be developed that consists of an engineered commensal skin bacterial species that is able to establish residence on a skin model and secretes a desired protein that can penetrate the stratum corneum. The small business partner, Azitra Inc., is currently developing preclinical candidates using bacterial systems for in situ protein delivery for treating skin diseases. The academic partner, Yale University, has world-class facilities and subject matter expertise to co-direct experimentation and key analyses. Together, we are aiming to test if this platform is a viable approach as a therapeutic for treating a range of skin diseases by simultaneously modulating the skin microbiome and secreting proteins in situ for therapeutic benefit.
Project Terms:
Address; Anti-Inflammatory Agents; Antibiotics; antimicrobial peptide; Atopic Dermatitis; Bacteria; Bacterial Proteins; base; Biological Assay; Biological Models; Businesses; Calcineurin inhibitor; Cells; Characteristics; Chronic; Confocal Microscopy; cost; Coupled; Data; Defect; Dermal; Development; Disease; DNA Sequence Alteration; Ecology; Engineering; Epidermis; Experimental Designs; expression vector; filaggrin; Gene Mutation; Genes; Genetic; Genetic Skin Diseases; Grant; Growth; Health Care Costs; Histology; Human; Ichthyosis Vulgaris; Image; imaging system; Immunohistochemistry; In Situ; In Vitro; in vitro Model; Inflammatory; interest; keratinocyte; Location; loss of function mutation; Measures; microbial; microbiome; Modeling; Mutation; novel strategies; Ointments; Patients; Penetration; Peptides; Phase; Physiology; Population; pre-clinical; Pre-Clinical Model; Predisposition; Production; Property; Protein Export Pathway; Proteins; Reapplication; Recombinants; Regulatory T-Lymphocyte; Research; residence; Resolution; Role; Signal Transduction; Skin; skin barrier; skin disorder; skin microbiome; Small Business Technology Transfer Research; Staging; Staphylococcus aureus; Staphylococcus epidermidis; Stratum corneum; Structure; Supplementation; System; Testing; Therapeutic; therapeutic protein; Therapeutic Uses; Time; Topical application; Topical Corticosteroids; treatment adherence; Universities
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00